I partner with life sciences and technology companies to accomplish their general legal objectives, as well as guide them through financing transactions and public company reporting and compliance.
Sean Clayton heads Cooley’s San Diego corporate practice. Sean's practice focuses on the representation of public and private growth companies in general corporate matters, as well as a wide range of transactions, including public offerings, venture capital financings and M&A.
Download full bio
Horizon Therapeutics to Acquire Viela Bio
Inhibrx – $137 Million IPO
Poseida Therapeutics – $224 Million IPO
Pliant Therapeutics - $166 Million IPO
ORIC Pharmaceuticals - $138 Million IPO
Mergers & Acquisitions
Don’t know how Cooley does it but they always pull out great attorneys to work with and you are certainly that. We really appreciate your knowledge, experience and counsel through this process.
Stanford Law SchoolJD, Order of the Coif, 2003
University of California, San DiegoBA, Political Science and Economicssumma cum laude, Phi Beta Kappa, 2000
Horizon Therapeutics to Acquire Viela Bio to Grow Rare Disease Medicine Portfolio
February 5, 2021
Gossamer Bio – $317 Million IPO
February 21, 2019
ASLAN Pharmaceuticals – $42 Million IPO
June 8, 2018
+1 858 550 6034